|Table of Contents|

Relationship between TP53 gene mutation and prognosis of oral squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 11
Page:
2169-2172
Research Field:
Publishing date:

Info

Title:
Relationship between TP53 gene mutation and prognosis of oral squamous cell carcinoma
Author(s):
ZHANG Chen; LI Chunming
Department of Oral and Maxillofacial Surgery,The Second Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150000，China.
Keywords:
TP53; p53; oral squamous cell carcinoma; diagnosis and treatment
PACS:
R739.8
DOI:
10.3969/j.issn.1672-4992.2023.11.036
Abstract:
Oral squamous cell carcinoma(OSCC) is the most common pathological type in oral cancer and the main cause of morbidity and death in patients with head and neck cancer.The current treatments for OSCC patients include a variety of therapies including surgery,chemotherapy,biological therapy and radiation therapy.Despite recent advances in these treatments,the overall survival rate in the past few years has remained poor.As an important tumor suppressor gene,the TP53 gene has always been a hot spot in tumor molecular biology research.In recent years,many studies have shown that TP53 mutations are related to the decreased survival rate of OSCC patients and poor prognosis such as tumor resistance to radiotherapy and chemotherapy.This makes TP53 mutation status a potentially useful molecular marker for the prognosis and clinical response prediction of these patients.In order to gain a deeper understanding of the clinical value of TP53 gene in OSCC diagnosis and treatment,this article intends to review the relationship between TP53 gene mutation and OSCC prognosis and treatment research progress.

References:

[1]张斌.口腔鳞状细胞癌的表观遗传学研究现状和进展［J］.口腔颌面外科杂志,2016,26(2):77-82. ZHANG B.The research status and progress of epigenetics of oral squamous cell carcinoma ［J］.Journal of Oral and Maxillofacial Surgery,2016,26(2):77-82.
[2]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA Cancer J Clin,2020,70(1):7-30.
[3]M DU,R NAIR,L JAMIESON,et al.Incidence trends of lip,oral cavity and pharyngeal cancers:Global burden of disease 1990-2017［J］.Journal of Dental Research,2020,99(2):143-151.
[4]WONG TSC,WIESENFELD D.Oral cancer［J］.Australian Dental Journal,2018,63(Suppl 1):S91-S99.
[5]EDWARDSZOE C,TROTTER ELEANOR W,TORRES-AYUSO PEDRO,et al.Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of mutant p53［J］.Cancer Research,2017,77(18):4961-4972.
[6]DONEHOWER LA,SOUSSI T,KORKUT A,et al.Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas［J］.Cell Reports Vol,2019,28(11):1370-1384.
[7]朱宇星,沈文怡.TP53基因与髓系肿瘤［J］.国际输血及血液学杂志,2017,40(05):408-412. ZHU YX,SHEN WY.TP53 gene and myeloid tumors［J］.International Journal of Blood Transfusion and Hematology,2017,40(05):408-412.
[8]HU W,CHEN S,THORNE RF,et al.TP53,TP53 target genes(DRAM,TIGAR) and autophagy［J］.Adv Exp Med Biol,2019,1206:127-149.
[9]吴雪芳,李霜,胡建军,等.结直肠癌中K-RAS基因突变与p53蛋白表达的临床意义及相关性［J］.临床与实验病理学杂志,2020,36(10):1215-1218. WU XF,LI S,HU JJ,et al.The clinical significance and correlation between K-RAS gene mutation and p53 protein expression in colorectal cancer［J］.Journal of Clinical and Experimental Pathology,2020,36(10):1215-1218.
[10]PANDYA JA,NATARAJAN S.A correlation of immunohistochemical expression of TP53 and severity of inflammation with varying grades of oral squamous cell carcinoma［J］.Journal of Cancer Research and Therapeutics,2019,15(3):564-570.
[11]COHEN EEW,BELL RB,BIFULCO CB,et al.The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck(HNSCC)［J］.Journal for Immunotherapy of Cancer,2019,7(1):184.
[12]SOLOMON B,YOUNG RJ,RISCHIN D.Head and neck squamous cell carcinoma:Genomics and emerging biomarkers for immunomodulatory cancer treatments［J］.Seminars in Cancer Biology,2018,52(Pt 2):228-240.
[13]YAMAMOTO S,IWAKUMA T.Regulators of oncogenic mutant TP53 gain of function［J］.Cancers,2018,11(1):4.
[14]LAPKE N,LU YJ,LIAO CT,et al.Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma［J］.Oncotarget,2016,7(28):44194-44210.
[15]OIKAWA Y,MORITA KI,KAYAMORI K,et al.Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma［J］.Cancer Science,2017,108(2):56-66.
[16]DEVARAJA K.Current prospects of molecular therapeutics in head and neck squamous cell carcinoma［J］.Pharmaceutical Medicine,2019,33(4):269-289.
[17]RIVERA C,OLIVEIRA AK,COSTA RAP,et al.Prognostic biomarkers in oral squamous cell carcinoma:A systematic review［J］.Oral Oncol,2017,72:38-47.
[18]PICKERING CR,ZHANG J,YOO SY,et al.Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers［J］.Cancer Discovery,2013,3(7):770-781.
[19]LI VD,LI KH,LI JT.TP53 mutations as potential prognostic markers for specific cancers:analysis of data from The cancer genome atlas and the international agency for research on cancer TP53 database［J］.J Cancer Res Clin Oncol,2019,145(3):625-636.
[20]NESKEY DM,OSMAN AA,OW TJ,et al.Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer［J］.Cancer Res,2015,75(7):1527-1536.
[21]LI X,SHAO C,SHI Y,et al.Lessons learned from the blockade of immune checkpoints in cancer immunotherapy［J］.J Hematol Oncol,2018,11(1):31.
[22]BRAUN DA,BURKE KP,VAN ALLEN EM.Genomic approaches to understanding response and resistance to immunotherapy［J］.Clin Cancer Res,2016,22(23):5642-5650.
[23]LYU H,LI M,JIANG Z,et al.Correlate the TP53 mutation and the HRAS mutation with immune signatures in head and neck squamous cell cancer［J］.Comput Struct Biotechnol J,2019,17:1020-1030.
[24]OSMAN AA,NESKEY DM,KATSONIS P,et al.Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients［J］.Cancer Res,2015,75(7):1205-1215.
[25]PILBOROUGH AE,LAMBERT DW,KHURRAM SA.Extranodal extension in oral cancer:A role for the nodal microenvironment［J］.J Oral Pathol Med,2019,48(10):863-870.
[26]GLEBER-NETTO FO,NESKEY D,COSTA AFM,et al.Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma［J］.Cancer,2020,126(20):4498-4510.
[27]SANDULACHE VC,MICHIKAWA C,KATARIA P,et al.High-risk TP53 mutations are associated with extranodal extension in oral cavity squamous cell carcinoma［J］.Clin Cancer Res,2018,24(7):1727-1733.
[28]NAGARAJAN P.Differentiating keratoacanthoma from squamous cell carcinoma-In quest of the holy grail［J］.J Cutan Pathol,2020,47(4):418-420.
[29]CABIBI D,CONWAY DE MACARIO E,INGRAO S,et al.CD1A-positive cells and HSP60(HSPD1) levels in keratoacanthoma and SCC［J］.Cell Stress Chaperones,2016,21(1):131-137.
[30]TURAN G,ALTUN E,ASLAN F,et al.The role of p53,Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC［J］.Indian J Pathol Microbiol,2019,62(4):561-565.
[31]XIA Y,LI X,SUN W.Applications of recombinant adenovirus-p53 gene therapy for cancers in the clinic in China［J］.Curr Gene Ther,2020,20(2):127-141.
[32]ZHANG WW,LI L,LI D,et al.The first approved gene therapy product for cancer Ad-p53(Gendicine):12 years in the clinic［J］.Hum Gene Ther,2018,29(2):160-179.
[33]MOORE EC,SUN L,CLAVIJO PE,et al.Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms［J］.Oncoimmunology,2018,7(7):e1404216.
[34]LINDEMANN A,TAKAHASHI H,PATTEL AA,et al.Targeting the DNA damage response in OSCC with TP53 mutations［J］.J Dent Res,2018,97(6):635-644.
[35]YU X,BLANDEN A,TSANG AT,et al.Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53［J］.Mol Pharmacol,2017,91(6):567-575.
[36]ZHANG Y,XU L,CHANG Y,et al.Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC［J］.Prostate Cancer Prostatic Dis,2020,23(1):160-171.
[37]LINDEMANN A,PATEL AA,SILVER NL,et al.COTI-2,A Novel thiosemicarbazone derivative,exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms［J］.Clin Cancer Res,2019,25(18):5650-5662.
[38]ZUEHLKE AD,MOSES MA,NECKERS L.Heat shock protein 90:its inhibition and function［J］.Philos Trans R Soc Lond B Biol Sci,2018,373(1738):20160527.
[39]ALEXANDROVA EM,MIRZA SA,XU S,et al.p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo［J］.Cell Death Dis,2017,8(3):e2661.
[40]PARRALES A,IWAKUMA T.Targeting oncogenic mutant p53 for cancer therapy［J］.Front Oncol,2015,5:288.
[41]WANG Y,JANKU F,PIHA-PAUL S,et al.Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies［J］.Sci Rep,2020,10(1):3080.

Memo

Memo:
黑龙江省自然科学基金（编号：LH2021H033）
Last Update: 2023-04-28